APRIL 7, 2021

Stanislas Veillet, CEO of Biophytis, reviews the company’s latest news in this interview with Laurent Grassin from Journal des Biotechs, covering listing on Nasdaq, Covid-19 clinical studies, expected clinical data in sarcopenia and the legal case with Negma.  You can see the interview here

11 may 2017

The SARA clinical program – Towards a first treatment for Sarcopenia. Interviews conducted during ICSFR 2017. Watch the video